Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

Related Content:

Management of Chemotherapy-Ineligible AML: Beyond HMA MonotherapyAcute Lymphoblastic Leukemia

FDA Grants Fast Track and Rare Pediatric Disease Designation to WU-CART-007 in R/R T-Cell ALL/LBL

Recap: Fellows at MSK and Moffitt ‘Face Off’ to Discuss Treatment Strategies in Older Patients With ALL

Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab